newsfilter
← Latest News
GlobeNewswire·

Viracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide,